Politics ❯ Healthcare Policy

Drug Pricing

Government Regulations US Government Bernie Sanders NHS Funding Senate Hearings US Senate Public Health High-cost Drugs Political Pressure Equity Across Developed Countries Consumer Access U.S. Politics Pharmaceutical Companies Inflation Reduction Act US Administration Pharmaceutical Industry Regulatory Issues Pharmaceutical Regulations Eli Lilly IVF Treatments Medicare Regulatory Environment Government Involvement U.S. Policy Insurance Regulation Public Messaging Most-Favored-Nation Deals Provincial Regulations Public Funding

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Strong oncology growth offset Stelara’s drop.

Oz Defends Trump’s Drug-Price Math on NBC as Fact-Checks Reject Claims of Cuts Over 100 Percent

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks